Ophthalmology:早产儿视网膜病变(ROP)新的危险因素被确定

2016-04-18 崔倩 译 MedSci原创

这项研究的目的之一是确定早产儿视网膜病变(ROP)的“新”统计独立危险因素。另一个目标是评估任何新的风险因素是否可以解释治疗要求苛刻的ROP发生率的增加。来自丹麦的研究人员进行了一项回顾性,注册为基础的队列研究。这项研究的参与者为1997年至2008年出生在丹麦的早产儿(n=6490)。研究样本和31个候选的危险因素在3个国家登记册进行确定。数据被链接到一个独特的民事登记号码。31个候选的危险因素

该研究的目的之一是确定早产儿视网膜病变(ROP)的“新”统计独立危险因素。另一个目标是评估任何新的风险因素是否可以解释治疗要求苛刻的ROP发生率的增加。

来自丹麦的研究人员进行了一项回顾性、注册为基础的队列研究。这项研究的参与者为1997年至2008年在丹麦出生的早产儿(n=6490)。

研究样本和31个候选的危险因素在3个国家登记册进行确定。数据被链接到一个独特的民事登记号码。31个候选的危险因素在单变量分析中进行评估,同时调整了已知的危险因素(即分娩时的孕龄[GA]、小于胎龄[SGA]、多胎和男性)。显著性成果在一个多元逻辑回归模型中被分析。

主要结果指标为ROP和其与候选危险因素的联系。

除了分娩时的GA、SGA、多胎、和男性,机械通气(比值比[OR],2.84;95%可信区间[CI],1.99-4.08; P<0.01)和输血(OR,1.97; 95%CI,1.20-3.14; P=0.01)是唯一的新统计独立的危险因素。ROP这些预后因素的修正没有引起ROP发生率的增加。

在一个大的研究人群中,输血和机械通气是预测ROP发展唯一的新统计的独立危险因素。在新生儿治疗时,改良机械通气或输血不会导致在最近时期出生(2003-2008)的早产儿中ROP的发生率增加。

原始出处:

Slidsborg C,Jensen A,Forman JL,et al.Neonatal Risk Factors for Treatment-Demanding Retinopathy of Prematurity,Ophthalmology,2016.4.18

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1269828, encodeId=9c59126982802, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413869, encodeId=1d0414138696b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541154, encodeId=9f52154115446, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543159, encodeId=4f641543159f0, content=<a href='/topic/show?id=d8d6592e21d' target=_blank style='color:#2F92EE;'>#早产儿视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59272, encryptionId=d8d6592e21d, topicName=早产儿视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d29113549501, createdName=396094184_42047359, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79692, encodeId=9b69e969223, content=学习了…, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:07:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79693, encodeId=a70fe96934c, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:07:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2016-04-20 zutt
  2. [GetPortalCommentsPageByObjectIdResponse(id=1269828, encodeId=9c59126982802, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413869, encodeId=1d0414138696b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541154, encodeId=9f52154115446, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543159, encodeId=4f641543159f0, content=<a href='/topic/show?id=d8d6592e21d' target=_blank style='color:#2F92EE;'>#早产儿视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59272, encryptionId=d8d6592e21d, topicName=早产儿视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d29113549501, createdName=396094184_42047359, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79692, encodeId=9b69e969223, content=学习了…, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:07:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79693, encodeId=a70fe96934c, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:07:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1269828, encodeId=9c59126982802, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413869, encodeId=1d0414138696b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541154, encodeId=9f52154115446, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543159, encodeId=4f641543159f0, content=<a href='/topic/show?id=d8d6592e21d' target=_blank style='color:#2F92EE;'>#早产儿视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59272, encryptionId=d8d6592e21d, topicName=早产儿视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d29113549501, createdName=396094184_42047359, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79692, encodeId=9b69e969223, content=学习了…, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:07:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79693, encodeId=a70fe96934c, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:07:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1269828, encodeId=9c59126982802, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413869, encodeId=1d0414138696b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541154, encodeId=9f52154115446, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543159, encodeId=4f641543159f0, content=<a href='/topic/show?id=d8d6592e21d' target=_blank style='color:#2F92EE;'>#早产儿视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59272, encryptionId=d8d6592e21d, topicName=早产儿视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d29113549501, createdName=396094184_42047359, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79692, encodeId=9b69e969223, content=学习了…, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:07:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79693, encodeId=a70fe96934c, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:07:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1269828, encodeId=9c59126982802, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413869, encodeId=1d0414138696b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541154, encodeId=9f52154115446, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543159, encodeId=4f641543159f0, content=<a href='/topic/show?id=d8d6592e21d' target=_blank style='color:#2F92EE;'>#早产儿视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59272, encryptionId=d8d6592e21d, topicName=早产儿视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d29113549501, createdName=396094184_42047359, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79692, encodeId=9b69e969223, content=学习了…, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:07:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79693, encodeId=a70fe96934c, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:07:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2016-04-19 李继凯

    学习了…

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1269828, encodeId=9c59126982802, content=<a href='/topic/show?id=979690e33bd' target=_blank style='color:#2F92EE;'>#视网膜#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90733, encryptionId=979690e33bd, topicName=视网膜)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=742793, createdName=zutt, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1413869, encodeId=1d0414138696b, content=<a href='/topic/show?id=27b290e82f4' target=_blank style='color:#2F92EE;'>#视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90782, encryptionId=27b290e82f4, topicName=视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7143034078, createdName=zhanfl, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1541154, encodeId=9f52154115446, content=<a href='/topic/show?id=5c961e37307' target=_blank style='color:#2F92EE;'>#THA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=17373, encryptionId=5c961e37307, topicName=THA)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=615b13300589, createdName=1249842em13(暂无昵称), createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1543159, encodeId=4f641543159f0, content=<a href='/topic/show?id=d8d6592e21d' target=_blank style='color:#2F92EE;'>#早产儿视网膜病变#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59272, encryptionId=d8d6592e21d, topicName=早产儿视网膜病变)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d29113549501, createdName=396094184_42047359, createdTime=Wed Apr 20 08:55:00 CST 2016, time=2016-04-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79692, encodeId=9b69e969223, content=学习了…, beContent=null, objectType=article, channel=null, level=null, likeNumber=138, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:07:00 CST 2016, time=2016-04-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=79693, encodeId=a70fe96934c, content=不错的文章, beContent=null, objectType=article, channel=null, level=null, likeNumber=115, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=240a1683959, createdName=李继凯, createdTime=Tue Apr 19 19:07:00 CST 2016, time=2016-04-19, status=1, ipAttribution=)]
    2016-04-19 李继凯

    不错的文章

    0

相关资讯

JAMA:预防使用氟康唑不减少早产儿念珠菌病发生或死亡

侵袭性念珠菌病是早产儿迟发性感染的重要原因,临床体征往往表现细微。尽管采取抗真菌治疗,但其在早产儿中后果严重。伴随着念珠菌感染,近70%出生体重小于1000g的婴儿发生严重的神经发育障碍或死亡。既往随机安慰剂对照试验已表明,氟康唑预防性治疗可减少新生儿重症监护室(NICUs)侵袭性念珠菌病的发病率,以及念珠菌病的高疾病负担(≥15%)。 目前指南推荐包括在新生儿重症监护室中,对侵袭性念珠菌发病率较